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Economic Effects of Extended
Clopidogrel Therapy—A Word of Caution
In the February 1 issue of the Journal, Cowper et al. (1) compared
the outcomes and costs of extending clopidogrel therapy (in
addition to aspirin) from one month to one year after percutaneous
coronary intervention (PCI), with withdrawal of clopidogrel after
one month. Unpublished per-protocol data from the Clopidogrel
for the Reduction of Events During Observation (CREDO) trial
(2) were used to estimate the effects of long-term clopidogrel use
on event rates in a sample of patients at the Duke Medical Center
undergoing PCI and receiving clopidogrel for only one month
after the procedure. The investigators concluded that clopidogrel
therapy for one year after PCI is economically attractive in respect
to cost per year of life saved, particularly in high-risk patients.
However, the conclusions of Cowper et al. (1) rest solely on the
assumption that clopidogrel between one month and one year after
PCI significantly reduces the incidence of myocardial infarction
(MI). The relative risk (RR) of MI was estimated to be 0.56 with
clopidogrel long-term, but the 95% confidence interval (CI) was
0.3 to 1.0, suggesting a possibility of no effect at all. Consequently,
the costs per year of life saved may actually be unlimited, as shown
in Figure 2 in the study by Cowper et al. (1). Moreover, by using
per-protocol rather than intent-to-treat data, an even distribution
of confounders produced by randomization was altered, which may
have incorrectly favored extended clopidogrel therapy. In fact, the
one-year intention-to-treat analysis of the CREDO trial did not
show a significant reduction of MI between day 0 and one year or
between one month and one year (RR reduction between day 0 to
one year, 21.7%; 95% CI 7.1% to 42.7%) (2,3). Similarly, the
observational PCI substudy of the Clopidogrel in Unstable Angina
to Prevent Recurrent Events (CURE) trial (4) did not show an
advantage of long-term clopidogrel use over placebo in terms of
death or MI beyond 30 days after PCI (RR reduction 23%; 95%
CI, 17% to 50%) (5).
An increase of major bleeding occurs when clopidogrel is added
to aspirin long-term (2,6,7), and bleeding (like MIs) may influence
prognosis adversely (8). Only the costs of bleeding, but not a
potential negative effect on life expectancy, were incorporated into
the model used by Cowper et al. (1). In addition, the low
compliance with therapy in the CREDO trial (60%) may have
obscured the true risk of severe bleedings with dual antiplatelet
therapy.
Finally, the conclusions of Cowper et al. (1) should be viewed
with caution—they seem overenthusiastic and may be incorrect.
Health economics cannot help to guide decisions on therapy when
there is no firm evidence of clinical efficacy. Combining clopi-
dogrel and aspirin long-term may actually do more harm than
good.
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REPLY
Dr. Eriksson is correct in noting that our results hinge on the
ability of clopidogrel to reduce the incidence of myocardial
infarction (MI) between one month and one year after percutane-
ous coronary intervention (PCI), a point we emphasized in our
report (1). Although Dr. Eriksson is also technically correct in
pointing out that, as the confidence interval for relative risk (RR)
for MI ranged from 0.3 to 1.0, there is a possibility that
Clopidogrel has no effect on MI, we do not consider this to be a
likely scenario. The point estimate (0.56) is the best estimate of
RR. Because the Clopidogrel for the Reduction of Events During
Observation (CREDO) trial was not powered to detect differences
in individual components of the combined end point, borderline
s i g n i fi c a n c e
(p  0.05) for MI, one of the components, is not surprising.
Dr. Eriksson also expressed concern that the per-protocol
population may not have been balanced between groups with
respect to confounders, causing the analysis to favor clopidogrel
therapy. However, we found no differences between the treatment
groups in baseline clinical characteristics of per-protocol patients.
Furthermore, although the reduction in MI between one month
and one year in the intention-to-treat population was not signif-
1376 Correspondence JACC Vol. 46, No. 7, 2005
October 4, 2005:1373–7
icant (p  0.14), a consistent beneficial effect was observed for all
components of the combined end point (MI, death, stroke), with
a significant reduction in the combined end point (2).
Dr. Eriksson also suggested that a potential negative effect of
bleeding on life expectancy should have been incorporated into the
model. Although bleeding may be associated with worse outcomes,
the extent to which bleeding independently increases the risk of
death (rather than being associated with other factors predictive of
death) has not been established. Given the low baseline rate of
bleeding in the CREDO trial, incorporating such an effect would
have a negligible impact on our results in any case.
Finally, Dr. Eriksson postulated that the low compliance rate in
the CREDO trial obscured the risk of bleeding. It is true that the
risk of bleeding in the CREDO trial may have been underesti-
mated because of the low compliance rate (62%). By the same
token, the benefits of treatment in the CREDO trial may also have
been underestimated. Compliance also affects the cost of therapy.
In the cost-effectiveness analysis, we adopted the conservative
approach of assigning to the treatment group the full cost of
clopidogrel (assuming full compliance), rather than the actual cost
of clopidogrel based on the observed compliance rate in the
CREDO trial.
In conclusion, we believe our analysis incorporates the best
available estimates of the clinical effectiveness of long-term clopi-
dogrel therapy. We look forward to the results of the Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance (CHARISMA) study, which should
further inform discussion regarding the value of long-term clopi-
dogrel therapy.
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CORRECTION
Biagini E, Elhendy A, Schinkel AFL, Bax JJ, Rizzello V, van Domburg RT, Rapezzi C, Simoons ML, Poldermans D. Risk
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Echocardiography. J Am Coll Cardiol 2004;46:730 –2.
An author’s name was printed incorrectly as Rizzello Vittoria, MD. The correct author’s name is Vittoria Rizzello, MD. The authors regret
this error.
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